STR3/19
B-cell dependent autoimmune diseases (e.g., SLE, rheumatoid arthritis, multiple sclerosis)
Key Facts
About Strike Pharma
Strike Pharma is an early-stage biotechnology company pioneering a novel approach to in vivo CAR-T therapy through targeted LNP delivery. Its core technology is based on a high-affinity, picomolar interaction between a proprietary synthetic peptide tag (pTag) and an scFv antibody fragment, allowing for the post-storage conjugation of targeting antibodies to LNPs. This platform aims to overcome key challenges in CAR-T manufacturing, storage, and administration, offering a potential off-the-shelf, non-viral alternative to current ex vivo CAR-T and in vivo viral vector approaches. The company's lead concept candidate, STR3/19, targets B-cell driven autoimmune diseases.
View full company profile